Market Trends of Global Absorbable Tissue Spacer Industry
The Radiotherapy Segment to Hold Significant Share in the Global Absorbable Tissue Spacer Market Over the Forecast Period
The radiotherapy segment is expected to witness significant market growth over the forecast period owing to factors such as the rising prevalence of cancer and the rising adoption of spacers during radiotherapy in treating various cancer types. For instance, according to an article published by BioMed Central Ltd in April 2022, the number of new cancer cases is estimated to increase by 20% by 2030 in Germany. Additionally, according to the American Association for Cancer Research (AACR) Cancer Progress Report 2022, in the past three years, there was an increase in the number of cancer survivors living in the United States, reaching more than 18 million as of January 1, 2022.
Additionally, the rising adoption of spacers during radiotherapy in treating various cancer types contributes to the segment's growth. For instance, according to an article published by the Journal of Radiation Research in July 2022, spacers had a favorable efficacy in managing prostate radiotherapy in both external beam radiation therapy (EBRT) and brachytherapy. The rise in research studies demonstrating the use of tissue spacers after radiotherapy further facilitates segment growth over the forecast period. For instance, according to the article published in January 2023 in the Radiation Oncology Journal, even though the higher radiation dose to the prostate can improve the overall outcome, dose escalation significantly increases the risk of treatment toxicity.
Thus, the increase in cancer cases and significant advantages offered by absorbable tissue spacers during radiotherapy contribute to the market segment's growth.
North America Dominates the Absorbable Tissue Spacer Market and Expects to do the Same Over the Forecast Period
North America is expected to show significant growth in the absorbable tissue spacer market owing to factors such as the increasing incidence and prevalence of cancers and progressing technological advancements in cancer treatment. For instance, according to the American Cancer Society update, in January 2023, an estimated 288,300 new prostate cancer cases and 52,550 new colon and rectum cases were reported in the United States.
In addition, the use of injectable rectal spacers to distance the anterior rectum from the prostate is a potential strategy to reduce the dose of unintended radiation to the rectum. For instance, according to an article published by MDPI in October 2022, hydrogel spacers are gaining increasing popularity in the treatment regimen for prostate cancer in the United States. After the FDA approval of SpaceOAR, specialists received more referrals for hydrogel placements. Such advancement in cancer treatment is expected to drive the market's growth over the forecast period.
Furthermore, company players employ strategic initiatives to boost the market growth of absorbable tissue spacers. For instance, in October 2023, Teleflex Incorporated, the United States-based medical technologies company, completed the acquisition of Palette Life Sciences, Inc. This acquisition added Barrigel, a biodegradable sculptable rectal spacer, to Teleflex’s interventional urology portfolio.
Therefore, factors such as the increasing burden of prostate cancer and the advantages of tissue spacers in reducing complications and strategic initiatives taken by the market players boost the market growth in the North American region.
